Axsome Therapeutics (AXSM) Scheduled to Post Quarterly Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM) will be issuing its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 5th. The company reported ($1.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The company had revenue of $87.17 million during the quarter, compared to the consensus estimate of $84.53 million. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM opened at $87.25 on Tuesday. The firm has a market cap of $4.14 billion, a PE ratio of -13.40 and a beta of 1.26. Axsome Therapeutics has a 12-month low of $55.02 and a 12-month high of $98.40. The company has a quick ratio of 2.40, a current ratio of 2.48 and a debt-to-equity ratio of 1.77. The company’s 50 day moving average price is $90.19 and its two-hundred day moving average price is $83.07.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AXSM shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a research note on Monday, September 16th. HC Wainwright reissued a “buy” rating and set a $180.00 price target on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Bank of America raised Axsome Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $95.00 to $106.00 in a research report on Tuesday, August 6th. Royal Bank of Canada upped their price objective on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $130.00 target price on shares of Axsome Therapeutics in a research note on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $124.64.

Insider Activity at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the transaction, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $487,275.58. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the sale, the director now owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Mark L. Jacobson sold 47,739 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the completion of the transaction, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $487,275.58. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 22.40% of the stock is owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.